

1 BRIAN M. BOYNTON
2 Principal Deputy Assistant Attorney General

3 ARUN G. RAO
4 Deputy Assistant Attorney General

5 AMANDA N. LISKAMM
6 Director

7 HILARY K. PERKINS
8 Assistant Director

9 NOAH T. KATZEN
10 Trial Attorney
11 Consumer Protection Branch
12 U.S. Department of Justice
13 P.O. Box 386
14 Washington, DC 20044-0386
15 (202) 305-2428
16 (202) 514-8742 (fax)
17 Noah.T.Katzen@usdoj.gov

18 UNITED STATES DISTRICT COURT
19 FOR THE EASTERN DISTRICT OF WASHINGTON

20 STATE OF WASHINGTON, *et al.*,

21 Plaintiffs,

22 v.

23 U.S. FOOD AND DRUG
24 ADMINISTRATION, *et al.*,

25 Defendants.

No. 1:23-cv-03026

DEFENDANTS' MOTION FOR
CLARIFICATION

05/10/23

WITHOUT ORAL ARGUMENT

1 Plaintiffs challenge FDA’s January 3, 2023, approval of modifications to the
2 Risk Evaluation and Mitigation Strategy (REMS) for mifepristone.¹ On April 7,
3 2023, this Court declined to preliminarily enjoin FDA from enforcing or applying
4 any requirement of mifepristone’s REMS. Order at 26-27. But the Court
5 preliminarily enjoined the agency from “altering the status quo and rights as it
6 relates to the availability of Mifepristone under the current operative January 2023
7 Risk Evaluation and Mitigation Strategy [(REMS)] under 21 U.S.C. § 355-1 in
8 Plaintiff States.” Order at 30.
9
10
11

12 Shortly before this Court entered its order, the United States District Court
13 for the Northern District of Texas entered an order invoking 5 U.S.C. § 705 to stay
14 the approval of the new drug application and abbreviated new drug application for
15 mifepristone. *See Alliance for Hippocratic Medicine v. FDA*, 2:22-cv-00223-Z,
16 Dkt. 137 (Apr. 7, 2023). That court stayed its order for seven days to give FDA
17
18
19

20 ¹ This motion uses the term “mifepristone” to refer to drug products that are
21 approved for medical termination of early pregnancy, in both brand name and
22 generic form. FDA has separately approved another manufacturer’s drug, Korlym,
23 which has mifepristone as its active ingredient and is approved for the treatment of
24 Cushing’s syndrome. This litigation, including the Court’s order, does not affect
25 Korlym or its generic.
26
27

DEFENDANTS’ MOTION FOR CLARIFICATION

1 time to seek relief from the United States Court of Appeals for the Fifth Circuit,
2 and FDA is seeking an emergency stay pending appeal. But if the Texas district
3 court’s order takes effect, the order would—of its own force and without any
4 further action by FDA—stay the effectiveness of FDA’s prior approvals of
5 mifepristone nationwide. *See id.*
6
7

8 The result of that order appears to be in significant tension with this Court’s
9 order prohibiting FDA from “altering the status quo and rights as it relates to the
10 availability of Mifepristone” in Plaintiff States. Order at 30. The Court did not
11 address the interaction between the two orders, presumably because they were
12 issued less than 20 minutes apart. To ensure that Defendants comply with all court
13 orders in these unusual circumstances, Defendants respectfully request that this
14 Court clarify their obligations under its preliminary injunction in the event that the
15 *Alliance* order takes effect and stays the approval of mifepristone.
16
17
18
19
20
21
22
23
24
25
26
27

1 April 10, 2023

HILARY K. PERKINS
Assistant Director

2
3 /s/ Noah T. Katzen
4 NOAH T. KATZEN
5 Trial Attorney
6 Consumer Protection Branch
7 U.S. Department of Justice
8 P.O. Box 386
9 Washington, DC 20044-0386
10 (202) 305-2428
11 (202) 514-8742 (fax)
12 Noah.T.Katzen@usdoj.gov

Counsel for Defendants

13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
DEFENDANTS' MOTION FOR CLARIFICATION

CERTIFICATE OF SERVICE

I hereby certify that, on April 10, 2023, I electronically filed the foregoing with the Clerk of the Court using the CM/ECF system, which will send notification of such filing to all counsel of record.

/s/ Noah T. Katzen

NOAH T. KATZEN